Introduction {#Sec1}
============

Type 2 diabetes mellitus (T2DM) is a strong risk factor for cardiovascular disease (CVD). One of the main goals in T2DM management is to reduce the incidence of CVD through glycemic control and modification of risk factors for atherosclerosis \[[@CR1]\]. To achieve this goal, it is important to choose oral hypoglycemic agents (OHAs) that can slow down the progression of atherosclerosis.

Carotid artery intima media thickness (IMT) and its progression as evaluated by ultrasonography are well-established markers of atherosclerosis \[[@CR2]--[@CR4]\]. To evaluate the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on IMT, we previously conducted the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE). In this study, we demonstrated that sitagliptin attenuates the progression of carotid IMT in patients with T2DM treated with insulin without increasing the risk of hypoglycemia and weight gain compared to patients who received conventional therapy \[[@CR5]\].

After DPP-4 inhibitors were launched on the market in Japan in 2009, frequent hypoglycemic events were reported, especially in elderly patients with renal dysfunction treated with high-dose sulfonylureas in routine clinical settings \[[@CR6]\]. Taking these adverse effects of DPP-4 inhibitors into consideration, the Japan Association for Diabetes and Education Care committee on adequate use of incretin-based therapy released a warning that the dose of insulin should be reduced when it is used in combination with DPP-4 inhibitors \[[@CR7]\]. In response to this recommendation, in the SPIKE study we left the starting dose of sitagliptin to each investigator's discretion when it was used with insulin to avoid the risk of hypoglycemia. As a result, the dose of sitagliptin varied among patients in the sitagliptin treatment group even though sitagliptin improved glycemic control in a dose-dependent manner \[[@CR8]\]. In addition to its dose-dependent glucose-lowering effect, sitagliptin was associated with a dose-dependent reduction of the intima-media ratio in an obese rat model of diabetes \[[@CR9]\]. Nevertheless, we have not yet considered whether the dose of sitagliptin affects the progression of atherosclerosis. Thus, the aim of this post hoc analysis is to investigate the dose-dependent effect of sitagliptin on the progression of atherosclerosis.

Methods {#Sec2}
=======

Study Population {#Sec3}
----------------

We conducted a post hoc analysis of the SPIKE study, whose methods were described in detail previously \[[@CR5], [@CR10]--[@CR14]\]. Briefly, a total of 282 Japanese patients with T2DM treated with insulin and no past history of apparent CVD were randomly allocated to either the sitagliptin group (*n* = 142) or the conventional treatment group (*n* = 140). Randomization was performed using a dynamic allocation method based on age, gender, number of insulin injections daily, and concurrent pioglitazone use. Patients in the sitagliptin group were started on sitagliptin at 25 mg once daily in addition to ongoing insulin therapy. Initiation of sitagliptin at 50 mg once daily was permitted in patients not on any sulfonylureas. After 12 weeks of treatment with sitagliptin at 25 or 50 mg, the dose of sitagliptin was scheduled to increase to a maximum of 100 mg once daily if HbA1c was ≥7.0% (8.6 mmol/l) \[[@CR15]\]. However, participating physicians were allowed to reduce sitagliptin to 25 or 50 mg/day if treatment with 50 or 100 mg/day was considered to be poorly tolerated. Insulin dose adjustment was also permitted. In the conventional treatment group, either increasing the dose of current therapy (e.g., insulin) or the addition of OHAs was allowed to achieve optimal glycemic control \[[@CR15]\]. The addition of other DPP-4 inhibitors and glucagon-like peptide-1 (GLP-1) analogs was not allowed in either group. All patients who agreed to participate provided written informed consent before being enrolled into the study. The SPIKE study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000007396) and met the requirements of the International Committee of Medical Journal Editors.

Compliance with Ethical Guidelines {#Sec4}
----------------------------------

The study protocol was approved by the institutional review board of each participating institutionand complies with the current legal regulations in Japan. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients for being included in the study.

Measurement of Carotid IMT {#Sec5}
--------------------------

Each participant underwent ultrasonography of the carotid arteries by expert sonographers at the start of the study \[[@CR5], [@CR10]\]. All scans were electronically stored and emailed to the IMT Evaluation Committee (Osaka, Japan), where a single experienced reader blinded to the clinical characteristics of the patients interpreted them using automated digital edge-detection software (Intimascope; MediaCross, Tokyo, Japan). The software system evaluates an average of approximately 200 IMT values in a segment 2 cm proximal to the dilation of the carotid bulb (mean-IMT-CCA). Maximum IMT, including plaque lesions in the common carotid arteries (max-IMT-CCA), were measured separately.

Statistical Analysis {#Sec6}
--------------------

Results are presented as mean ± SD, medians (interquartile range), or number (proportion) of patients. Patients in the sitagliptin group were further classified into two subgroups based on whether their average dose of sitagliptin during the study period was greater than or equal to the median dose (higher sitagliptin dose group) or less than the median dose (lower sitagliptin dose group). We analyzed the differences between these two groups and the conventional group. Baseline and follow-up group comparisons were assessed using analysis of variance (ANOVA) for continuous variables and Fisher's exact test for categorical variables. Changes from baseline to 104 weeks were analyzed using a one-sample *t* test within each group. Differences in delta change in clinical parameters from baseline to 104 weeks among groups were analyzed with ANOVA followed by the Tukey-Kramer test. Differences in delta change in IMT from baseline to 104 weeks among groups were analyzed with analysis of covariance (ANCOVA) followed by the Tukey-Kramer test.

Trends in the change in IMT across the three groups were evaluated using linear regression analysis with an unadjusted model that included only the treatment group (henceforth, model 1) and the following models: model 2 (model 1 + age, gender, and baseline IMT), model 3 (model 2 + HbA1c at baseline, sulfonylurea use, and glinide use), and model 4 (model 3 + change in HbA1c from baseline to 104 weeks).

All statistical tests were two-sided with a significance level of 5%. All analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA).

Results {#Sec7}
=======

Results from the Original SPIKE Study {#Sec8}
-------------------------------------

Among a total of 282 participants, 137 in the sitagliptin group and 137 in the conventional treatment group were included in the full analysis set for the original study. Baseline clinical characteristics were comparable between the groups as previously described \[[@CR5]\]. In the original study, patients who received sitagliptin had significantly greater reductions in mean-IMT-CCA and left max-IMT-CCA but not right max-IMT-CCA than patients receiving conventional treatment \[[@CR5]\].

Baseline Characteristics {#Sec9}
------------------------

In this post hoc analysis, subjects were divided into three groups: the conventional treatment group (*n* = 137), lower sitagliptin dose group (*n* = 42; average dose about 5 mg *n* = 1, about10 mg *n* = 2, about 15 mg *n* = 1, about 20 mg *n* = 3, about 25 mg *n* = 18, about 40 mg *n* = 7, about 45 mg *n* = 10), and higher sitagliptin dose group (*n* = 95; average dose about 50 mg *n* = 54, about 55 mg *n* = 3, about 60 mg *n* = 1, about 65 mg *n* = 1, about 70 mg *n* = 4, about 75 mg *n* = 4, about 80 mg *n* = 5, about 85 mg *n* = 5, about 90 mg *n* = 18). The mean dose of sitagliptin was 53.2 mg/day (median 50 mg/day) among patients who received sitagliptin in the original study. The mean dose in the higher sitagliptin dose group was 63.3 mg/day, and the mean dose in the lower sitagliptin dose group was 30.5 mg/day. Demographic and baseline characteristics of the three groups were well balanced except for HbA1c, sulfonylurea use, and glinide use (Table [1](#Tab1){ref-type="table"}). During the study, five patients developed CVD (the conventional treatment group, *n* = 2; lower sitagliptin dose group, *n* = 1; higher sitagliptin dose group, *n* = 2, *P* = 0.85).Table 1Baseline clinical characteristics of patients by treatment groupParametersConventional treatment groupLower sitagliptin dose group\
(\<50 mg/day)Higher sitagliptin dose group\
(≥50 mg/day)*P* value (intergroup)Age (years)63.6 ± 10.0 (*n* = 137)65.3 ± 9.9 (*n* = 42)63.2 ± 9.6 (*n* = 95)0.51Male gender82 (59.9%)27 (64.3%)56 (58.9%)0.84Duration of diabetes (years)17.3 ± 8.7 (*n* = 134)17.6 ± 8.7 (*n* = 41)17.1 ± 8.4 (*n* = 94)0.96Body mass index (kg/m^2^)25.1 ± 3.4 (*n* = 137)24.6 ± 4.2 (*n* = 42)25.2 ± 4.4 (*n* = 95)0.74HbA1c (%)8.0 ± 1.0 (*n* = 137)7.7 ± 0.8 (*n* = 42)8.3 ± 1.1 (*n* = 95)0.002HbA1c (mmol/mol)63.9 ± 10.6 (*n* = 137)60.0 ± 8.8 (*n* = 42)67.1 ± 12.5 (*n* = 95)0.002Total cholesterol (mmol/l)4.94 ± 0.86 (*n* = 137)4.86 ± 0.73 (*n* = 41)5.08 ± 0.98 (*n* = 95)0.32LDL cholesterol (mmol/l)2.78 ± 0.70 (*n* = 136)2.84 ± 0.58 (*n* = 42)2.85 ± 0.85 (*n* = 95)0.74HDL cholesterol (mmol/l)1.39 ± 0.38 (*n* = 136)1.41 ± 0.40 (*n* = 42)1.48 ± 0.36 (*n* = 95)0.23Triglycerides (mmol/l)1.17 (0.90, 1.72) (*n* = 137)1.16 (0.89, 1.40) (*n* = 42)1.11 (0.79, 1.67) (*n* = 94)0.76Systolic BP (mmHg)132.0 ± 14.3 (*n* = 137)130.6 ± 16.5 (*n* = 42)130.0 ± 15.5 (*n* = 95)0.60Diastolic BP (mmHg)74.7 ± 12.0 (*n* = 137)76.8 ± 10.9 (*n* = 42)74.3 ± 11.1 (*n* = 95)0.48eGFR (ml/min/1.73 m^2^)79.7 ± 24.2 (*n* = 137)75.4 ± 17.9 (*n* = 42)78.7 ± 22.5 (*n* = 95)0.56UAE (mg/g creatinine)108.9 ± 224.3 (*n* = 134)83.4 ± 173.9 (*n* = 42)226.6 ± 666.6 (*n* = 94)0.08Number of insulin injections (times/day)2.9 ± 1.2 (*n* = 137)3.1 ± 1.0 (*n* = 42)2.8 ± 1.2 (*n* = 95)0.64Metformin48 (35.0)13 (31.0)36 (37.9)0.73Sulfonylurea15 (10.9)13 (31.0)4 (4.2)\<0.001Glinide19 (13.9)0 (0)2 (2.1)\<0.001Thiazolidinedione11 (8.0)4 (9.5)9 (9.5)0.88α-Glucosidase inhibitor42 (30.7)11 (26.2)30 (31.6)0.82Angiotensin-converting enzyme inhibitor4 (2.9)3 (7.1)5 (5.3)0.40Angiotensin II receptor blocker69 (50.4)17 (40.5)36 (37.9)0.15Statin63 (46.0)21 (50.0)45 (47.4)0.89Antiplatelet agent30 (21.9)12 (28.6)17 (17.9)0.36Data are number (%) of patients, mean ± SD, or medians (range)Differences in parameters among groups were analyzed by analysis of variance or Fisher's exact test*BP* blood pressure, *eGFR* estimated glomerular filtration rate, *UAE* urinary albumin excretion

Changes in Clinical Parameters in the Three Groups {#Sec10}
--------------------------------------------------

Although higher sitagliptin dose and conventional treatment both significantly reduced HbA1c levels from baseline, the improvement in HbA1c was significantly greater in the higher sitagliptin dose group (−0.62 ± 1.05%) than in the conventional treatment group (−0.20 ± 0.91%, *P* = 0.007), but not than the lower sitagliptin dose group (Table [2](#Tab2){ref-type="table"}). On the other hand, body mass index, blood pressure, lipid parameters, and renal function were not significantly different among the three groups during the observation period (Table [2](#Tab2){ref-type="table"}). With respect to hypoglycemic events, there was a significant difference in the mean number of events among the three groups (0.36 ± 0.80 episodes/month/person in the conventional treatment group, 0.67 ± 1.28 in the lower sitagliptin dose group, and 0.20 ± 0.52 in the higher sitagliptin dose group, *P* = 0.008 by ANOVA). On average, patients in the higher sitagliptin dose group had fewer hypoglycemic events than patients in the lower sitagliptin dose group (*P* = 0.006 by Tukey-Kramer test).Table 2Changes in clinical parameters from baseline to 104 weeks and frequency of hypoglycemic eventsParametersConventional treatment groupLower sitagliptin dose groupHigher sitagliptin dose group*P* value (intergroup)Body mass index (kg/m^2^)0.12 ± 1.77 (*n* = 117)0.04 ± 1.15 (*n* = 37)0.08 ± 1.62 (*n* = 82)0.96HbA1c (%)−0.20 ± 0.91 (*n* = 122)\*−0.25 ± 0.97 (*n* = 37)−0.62 ± 1.05 (*n* = 84)^§^0.008HbA1c (mmol/mol)−2.23 ± 9.99 (*n* = 122)\*−2.72 ± 10.61 (*n* = 37)−6.82 ± 11.52 (*n* = 84)^§^0.008Total cholesterol (%)−1.79 ± 14.60 (*n* = 122)1.16 ± 13.55 (*n* = 37)−4.44 ± 16.16 (*n* = 84)\*0.15LDL cholesterol (%)5.18 ± 23.93 (*n* = 121)\*3.39 ± 23.90 (*n* = 38)−0.20 ± 23.29 (*n* = 84)0.28HDL cholesterol (%)−0.46 ± 14.72 (*n* = 121)4.53 ± 16.21 (*n* = 37)−1.74 ± 14.49 (*n* = 84)0.10Triglycerides (%)−1.58 (−24.57, 16.67) (*n* = 122)−1.89 (−28.57, 49.06) (*n* = 37)0.00 (−24.22, 43.75) (*n* = 83)\*0.29Systolic BP (mmHg)2.52 ± 16.75 (*n* = 122)1.83 ± 18.71 (*n* = 36)−1.45 ± 19.11 (*n* = 83)0.29Diastolic BP (mmHg)2.19 ± 13.15 (*n* = 122)−1.00 ± 12.94 (*n* = 36)0.42 ± 10.05 (*n* = 83)0.32eGFR (ml/min/1.73 m^2^)−2.65 ± 11.76 (*n* = 122)\*−4.56 ± 8.69 (*n* = 36)^\#^−3.70 ± 11.00 (*n* = 84)^\#^0.61UAE (mg/g creatinine)23.9 ± 249.6 (*n* = 114)63.2 ± 222.3 (*n* = 35)−18.9 ± 356.4 (*n* = 79)0.34Frequency of hypoglycemic events (episodes/month/person)0.36 ± 0.800.67 ± 1.280.20 ± 0.520.008Data are mean ± SD, medians (interquartile range), or valuesDifferences in parameters from baseline to 104 weeks among groups were analyzed using analysis of varianceChanges from baseline to 104 weeks within a group were analyzed using a one-sample *t* test*BP* blood pressure, *eGFR* estimated glomerular filtration rate, *UAE* urinary albumin excretion\**P* \< 0.05, \#*P* \< 0.01, §*P* \< 0.001

Changes in IMT-CCA Among the Three Groups {#Sec11}
-----------------------------------------

Over 104 weeks, a higher sitagliptin dose was associated with reduced mean-IMT-CCA and left max-IMT-CCA relative to baseline (Table [3](#Tab3){ref-type="table"}), but not a lower sitagliptin dose or conventional treatment. In an ANOVA model that adjusted for group, age, gender, and IMT values at baseline, a higher sitagliptin dose significantly prevented progression of mean-IMT-CCA and tended to prevent progression of left max-IMT-CCA when compared with conventional treatment (Table [4](#Tab4){ref-type="table"}).Table 3IMT values at baseline and 104 weeks by treatment groupParameterConventional treatment groupLower sitagliptin dose groupHigher sitagliptin dose group*P* value (intergroup)Mean IMT-CCA (mm) Baseline (mm)0.84 ± 0.21 (*n* = 137)0.82 ± 0.21 (*n* = 42)0.85 ± 0.17 (*n* = 95)0.69 104 weeks (mm)0.86 ± 0.24 (*n* = 122)0.83 ± 0.24 (*n* = 38)0.81 ± 0.17 (*n* = 83)0.16*P* value (intragroup)0.060.610.001Right maximum IMT-CCA (mm) Baseline (mm)1.06 ± 0.40 (*n* = 137)1.05 ± 0.30 (*n* = 41)1.04 ± 0.28 (*n* = 95)0.91 104 week (mm)1.09 ± 0.49 (*n* = 122)1.11 ± 0.41 (*n* = 38)1.00 ± 0.30 (*n* = 83)0.26*P* value (intragroup)0.510.440.51Left maximum IMT-CCA (mm) Baseline (mm)1.11 ± 0.41 (*n* = 137)1.06 ± 0.34 (*n* = 42)1.12 ± 0.32 (*n* = 95)0.64 104 week (mm)1.12 ± 0.42 (*n* = 122)1.04 ± 0.32 (*n* = 38)1.03 ± 0.29 (*n* = 83)0.19*P* value (intragroup)0.390.880.010Data are mean ± SD. Differences in parameters among groups were analyzed using analysis of varianceDifferences in parameters from baseline to 104 weeks within a group were analyzed using a one-sample *t* test*CCA* common carotid artery, *IMT* intima-media thickness Table 4Changes in intima-media thickness among groupsParametersTreatment effect (mm)*P* value by ANCOVA*P* value by Tukey-KramerMean IMT-CCA (mm) Conventional treatment group vs. lower sitagliptin dose group−0.02 (−0.08, 0.05)0.0060.82 Conventional treatment group vs. higher sitagliptin dose group−0.07 (−0.12, −0.02)0.004 Lower sitagliptin dose group vs. higher sitagliptin dose group−0.05 (−0.12, 0.02)0.19Right maximum IMT-CCA (mm) Conventional treatment group vs. lower sitagliptin dose group0.02 (−0.13, 0.17)0.430.95 Conventional treatment group vs. higher sitagliptin dose group−0.05 (−0.17, 0.06)0.51 Lower sitagliptin dose group vs. higher sitagliptin dose group−0.08 (−0.24, 0.09)0.52Left maximum IMT-CCA (mm) Conventional treatment group vs. lower sitagliptin dose group−0.06 (−0.19, 0.07)0.060.51 Conventional treatment group vs. higher sitagliptin dose group−0.10 (−0.19, 0.00)0.05 Lower sitagliptin dose group vs. higher sitagliptin dose group−0.04 (−0.17, 0.10)0.79Data are mean differences (95% confidence interval)Differences in delta change in IMT from baseline to 104 weeks among groups (treatment effect) were analyzed with analysis of covariance after adjustment for baseline IMT, age, and gender followed by the Tukey-Kramer testTreatment effect = (Delta change in IMT from baseline to 104 weeks in the lower sitagliptin dose group) − (delta change in IMT from baseline 104 weeks in the conventional treatment group), (delta change in IMT from baseline 104 weeks in the higher sitagliptin dose) − (delta change in IMT from baseline 104 weeks in the conventional treatment group), or (delta change in IMT from baseline 104 weeks in the higher sitagliptin dose group) − (delta change in IMT from baseline 104 weeks in the lower sitagliptin dose group)*CCA* common carotid artery, *IMT* intima-media thickness

Furthermore, we investigated the dose-dependent effect of sitagliptin on the progression of atherosclerosis. Linear regression analysis showed a negative linear trend between treatment group and changes in IMT-CCA and left max-IMT-CCA, but not right max-IMT-CCA, in the unadjusted model (model 1) and adjusted models (models 2--4) (Table [5](#Tab5){ref-type="table"}). Similarly, there was a negative linear trend between the average dose of sitagliptin over 104 weeks (the dose of sitagliptin in the conventional treatment group was defined as 0 mg) and changes in IMT-CCA and left max-IMT-CCA, but not right max-IMT-CCA (Table [6](#Tab6){ref-type="table"}).Table 5Trends between sitagliptin dose when classified into three groups and change in IMTVariableRegression coefficient (SE)*P* valueChange in mean IMT-CCA Model 1−0.0015 (0.0004)\<0.001 Model 2−0.0013 (0.0004)0.002 Model 3−0.0014 (0.0004)\<0.001 Model 4−0.0014 (0.0004)0.002Change in right max IMT-CCA Model 1−0.0008 (0.0010)0.42 Model 2−0.0010 (0.0010)0.29 Model 3−0.0013 (0.0010)0.20 Model 4−0.0012 (0.0010)0.25Change in left max IMT-CCA Model 1−0.0022 (0.0009)0.014 Model 2−0.0019 (0.0008)0.018 Model 3−0.0023 (0.0008)0.006 Model 4−0.0023 (0.0009)0.008Estimation of a linear trend across sitagliptin dose, defined as the conventional treatment group, lower sitagliptin dose group, and higher sitagliptin dose group, is based on linear regression analysis with no adjustment (Model 1), adjustment for baseline IMT, age, and gender (Model 2), model 2 plus baseline HbA1c, sulfonylurea use, and glinide use (Model 3), and model 3 plus change in HbA1c (Model 4)*CCA* common carotid artery, *IMT* intima-media thickness Table 6Trend between average sitagliptin dose and change in IMTVariableRegression coefficient (SE)*P* valueChange in mean IMT-CCA Model 1−0.0010 (0.0003)0.003 Model 2−0.0008 (0.0003)0.009 Model 3−0.0009 (0.0003)0.006 Model 4−0.0008 (0.0003)0.010Change in right max IMT-CCA Model 1−0.0001 (0.0008)0.92 Model 2−0.0002 (0.0007)0.78 Model 3−0.0003 (0.0008)0.65 Model 4−0.0002 (0.0008)0.75Change in left max IMT-CCA Model 1−0.0013 (0.0007)0.046 Model 2−0.0012 (0.0006)0.06 Model 3−0.0014 (0.0006)0.022 Model 4−0.0014 (0.0006)0.030Estimation of a linear trend across sitagliptin dose is based on linear regression analysis with no adjustment (Model 1), adjustment for baseline IMT, age, and gender (Model 2), model 2 plus baseline HbA1c, sulfonylurea use, and glinide use (Model 3), and model 3 plus change in HbA1c (Model 4)*CCA* common carotid artery, *IMT* intima-media thickness

Discussion {#Sec12}
==========

In this post hoc study, sitagliptin as an addition to insulin therapy attenuated the progression of atherosclerosis in patients with T2DM in a dose-dependent manner. Thus, this finding lends support to the conclusion that this anti-atherosclerotic effect was due to the drug effect of sitagliptin itself.

A previous study demonstrated that sitagliptin inhibited plasma DPP-4 activity over 24 h and increased active GLP-1 levels in a dose-dependent manner after an oral glucose tolerance test, but there was no difference in effect on glucose excursion after an oral glucose tolerance test between a single oral 25- or 200-mg dose of sitagliptin \[[@CR16]\]. On the other hand, sitagliptin reduced HbA1c in a dose-dependent manner over 12 weeks in a longer-term study \[[@CR8]\]. In that study, the addition of sitagliptin to insulin therapy nearly dose-dependently reduced HbA1c levels over 104 weeks. From this point of view, one might expect that a higher dose of sitagliptin can significantly reduce carotid atherosclerosis through its glucose-lowering effects. In fact, a higher sitagliptin dose attenuated the progression of carotid atherosclerosis along with reducing HbA1c levels. However, sitagliptin treatment still attenuated the progression of mean-IMT-CCA and left max-IMT-CCA in a dose-dependent manner even after adjusting for changes in HbA1c from baseline. This suggests that sitagliptin treatment attenuated the progression of carotid artery atherosclerosis in a dose-dependent manner independent of its glucose-lowering effects.

The exact mechanism by which sitagliptin attenuates the progression of carotid IMT remains unclear in this post hoc analysis. One possibility is that sitagliptin slowed it down by enhancing GLP-1 signaling; a previous study demonstrated that sitagliptin increased GLP-1 activity in a dose-dependent manner after an oral glucose tolerance test \[[@CR16]\]. In fact, des-fluoro-sitagliptin was reported to inhibit macrophage inflammation through enhancement of GLP-1 signaling in a dose-dependent manner in an in vitro study \[[@CR17]\]. Another possibility is that DPP-4 inhibitors have the potential to inhibit the progression of atherosclerosis in a GLP-1--independent manner. DPP-4 inhibitors have various functions in vascular cells. In a rat model of diabetes \[[@CR9]\], sitagliptin reduced neointimal formation after carotid injury in a dose-dependent manner. In the same study, sitagliptin inhibited smooth muscle cell proliferation and monocyte adhesion in a dose-dependent manner independent of GLP-1 activity in vitro. Consistent with these findings, we previously demonstrated that anagliptin, another DPP-4 inhibitor, suppresses smooth muscle cell proliferation and reduces macrophage inflammation almost in a dose-dependent manner \[[@CR18]\]. Taken together, the anti-atherosclerotic effect of DPP-4 inhibitors may be independent of their glycemic effects in a dose-dependent manner; however, it is unclear whether the effects are mediated by GLP-1.

In this post hoc analysis, some investigators probably used lower doses of sitagliptin because of concerns about hypoglycemia when sitagliptin is used as an adjunct to insulin therapy. Unexpectedly, the number of hypoglycemic events was significantly higher in the lower sitagliptin dose group than in the higher sitagliptin dose treatment group. This may be associated with imbalances in sulfonylurea use among groups. In other words, add-on sitagliptin therapy increased the number of hypoglycemic events in patients on insulin and sulfonylurea combination therapy even though healthcare providers lowered the dose of sitagliptin. More episodes of hypoglycemia may reduce the beneficial effect of sitagliptin on the changes in carotid IMT. Indeed, we previously demonstrated that a higher frequency of hypoglycemia is associated with increases in carotid IMT \[[@CR14]\]. Thus, we should take precautions against potential hypoglycemia when DPP-4 inhibitors are added to insulin and sulfonylurea combination therapy. On the other hand, a higher sitagliptin dose attenuated the progression of carotid IMT without increasing the number of hypoglycemic events. Thus, we may consider using a higher dose of DPP-4 inhibitors from the perspective of preventing the progression of atherosclerosis while reducing the dose of insulin or reducing or discontinuing sulfonylurea therapy.

The present study has certain limitations. First, because this was an exploratory post hoc analysis of a randomized open-label trial, the findings may be limited. In particular, the classification of subgroups based on the average dose of sitagliptin may cause selection bias that interferes the results although we conducted the analysis adjusting for an imbalance in baseline characteristics among groups. Second, because these were exploratory analyses, the issue of multiple statistical comparisons becomes a concern, and findings should be interpreted with caution. Third, the carotid IMT results were not completely consistent, although the results tended to show a similar pattern. These differences may be associated with the underpowered sample and differences in carotid IMT by laterality \[[@CR19]\]. Fourth, the evaluation of average IMT by 0.01 mm may be difficult for non-experts in clinical practice although this method is well established and widely used in clinical studies. Fifth, we used surrogate markers for CVD as the primary endpoint. The reduction of IMT with sitagliptin treatment may be expected to be associated with a reduction in the onset of CVD considering the results of a meta-analysis showing that DPP-4 inhibitors have the potential to reduce the onset of CVD \[[@CR20]\]. However, our study lacked sufficient power to detect differences in the onset of CVD. Finally, the number of patients in the lower sitagliptin dose group was small.

Conclusions {#Sec13}
===========

Our data suggest that sitagliptin treatment is effective in attenuating the progression of carotid atherosclerosis in a dose-dependent manner in patients with T2DM on insulin therapy.
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